| | SLO | ENG | Cookies and privacy

Bigger font | Smaller font

Show document Help

Title:Vpliv izražanja mmd na odzivnost monocitov in makrofagov na adalimumab in vitro : magistrsko delo
Authors:ID Kralj, Adriana (Author)
ID Potočnik, Uroš (Mentor) More about this mentor... New window
ID Gole, Boris (Co-mentor)
Files:.pdf MAG_Kralj_Adriana_2023.pdf (2,80 MB)
MD5: B07290085D714D610B291AF9F89234E7
 
Language:Slovenian
Work type:Master's thesis/paper
Typology:2.09 - Master's Thesis
Organization:FKKT - Faculty of Chemistry and Chemical Engineering
Abstract:Parodontoza je pogosta vnetna bolezen, ki lahko vpliva na slabšo odzivanje bolnikov s sistemskimi boleznimi, kot je revmatoidni artritis, na biološko zdravilo adalimumab. Ugotovljeno je bilo, da stopnja revmatoidnega artritisa korelira z ravnijo izražanja MMD gena v makrofagih izoliranih iz sinovialne tekočine vnetih sklepov. Poleg tega stopnja izražanja MMD vpliva na klinični odziv bolnikov s kronično vnetno črevesno boleznijo na adalimumab. V magistrskem delu smo se odločili preveriti, kako se monociti in iz njih in vitro diferencirani makrofagi bolnikov s parodontozo odzivajo na biološko zdravilo adalimumab ter kakšno vlogo ima pri tem ekspresija MMD. Pri monocitih in iz njih diferenciranih makrofagih smo simulirali vnetje z dodatkom LPS in zdravljenje vnetja s komercialnim biološkim zdravilom adalimumab, ter preverili izražanje vnetnih genov IL1B, IL6 in TNFα. Adalimumab je učinkovito zavrl izražanje genov IL1B in IL6, ki v signalni kaskadi ležita nižje od TNFα, čeprav v primeru IL6 samo za monocite. Na izražanje TNFα dodatek adalimumaba ni imel vpliva. V magistrskem delu nismo dokazali vpliva MMD na učinkovitost adalimumaba pri zaviranju TNFα. Vendar zaradi teh ugotovitev ne moremo ovreči njegove potencialne vloge pri vplivu na učinkovitost adalimumaba, saj je potrebno izvesti še veliko raziskav s spremenjenimi eksperimentalnimi pogoji in tako potrditi ali ovreči vlogo MMD pri neučinkovitosti adalimumaba in s tem pripomoči k izboljšanju zdravljenja vnetnih bolezni.
Keywords:MMD, parodontoza, vnetni citokini, adalimumab, monociti, makrofagi, in vitro diferenciacija, in vitro vnetje, TNFα
Place of publishing:Maribor
Place of performance:Maribor
Publisher:[A. Kralj]
Year of publishing:2023
Number of pages:1 spletni vir (1 datoteka PDF (XI, 46 f.))
PID:20.500.12556/DKUM-84054 New window
UDC:[577:576.3]+615.281.9.015(043.2)
COBISS.SI-ID:152123651 New window
Publication date in DKUM:20.04.2023
Views:430
Downloads:58
Metadata:XML RDF-CHPDL DC-XML DC-RDF
Categories:KTFMB - FKKT
:
Copy citation
  
Average score:(0 votes)
Your score:Voting is allowed only for logged in users.
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:03.04.2023

Secondary language

Language:English
Title:The effect of mmd expression on the responsiveness of the monocytes and macrophages to adalimumab in vitro
Abstract:Periodontitis is a common inflammatory disease that may affect the response of patients with systemic diseases such as rheumatoid arthritis to the biologic drug adalimumab. The stage of rheumatoid arthritis was found to correlate with the level of MMD gene expression in macrophages isolated from the synovial fluid of inflamed joints. In addition, the level of MMD expression influences the clinical response of patients with chronic inflammatory bowel disease to adalimumab. In our master's thesis, we decided to check how monocytes and macrophages differentiated from them in vitro from patients with periodontitis respond to the biological drug adalimumab and what role MMD expression plays in this. In monocytes and macrophages differentiated from them, we simulated inflammation with the addition of LPS and the treatment of inflammation with the commercial biological drug adalimumab, and checked the expression of the inflammatory genes IL1B, IL6 and TNFα. Adalimumab effectively inhibited the expression of IL1B and IL6 genes, which lie downstream of TNFα in the signalling cascade, although in the case of IL6 only for monocytes. The expression of TNFα was not affected by adalimumab. In the master's thesis, we did not prove the effect of MMD expression on the effectiveness of adalimumab in inhibiting TNFα. However, due to these findings, we cannot evaluate its potential role in affecting the efficacy of adalimumab, as many more studies with modified experimental conditions are needed to confirm or assess the role of MMD in the ineffectiveness of adalimumab and thus help improve the treatment of inflammatory diseases.
Keywords:MMD, periodontitis, inflammatory cytokines, adalimumab, monocytes, macrophages, in vitro differentiation, in vitro inflammation, TNFα


Comments

Leave comment

You must log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back
Logos of partners University of Maribor University of Ljubljana University of Primorska University of Nova Gorica